The effectiveness of monafram in the treatment of acute coronary syndrome in critically ill patients

Aim. To study the effectiveness of monafram during percutaneous coronary intervention in patients with acute coronary syndrome in critical state. Material and methods. The results of emergency intervention were analyzed in 1794 patients with acute occlusion of the culprit artery, multifocal lesions of the coronary arteries. There were 2 equal groups of 794 patients each. In the 1st (main) group, Monafram was used before percutaneous coronary intervention; in the 2nd (control) group, the drug was not used. The efficiency of coronary blood flow reestablishment was evaluated according to the method of assessing the number of coronarography frames, when the revascularized artery was filled with a contrast agent: complete reestablishment of coronary blood flow was noted up to 20 frames, from 20 to 40 it was partial, and over 40 the coronary flow was not reestablished. The number of thrombotic complications after the intervention was recorded. Results. In group 1, coronary blood flow was completely reestablished in 56.7% of patients, partially — in 43.6%, and it was not reestablished in 0.7%; in group 2, in 46.4%, 51.9% and 1.7% of patients respectively. Thrombotic complications developed in 1.3% of patients in the 1st group, and in 4.5% of patients in the 2nd. Thrombosis did not develop when coronary blood flow was reestablished completely; it occurred in 0.2% when reestablished partially and in 61.9% of patients — when it was not reestablished. Conclusion. Monafram is highly effective in the prevention of the thrombotic complications development in critically ill patients.

1. Alekseeva Ya.V., Vyshlov E.V., Markov V.A. Deferred stent implantation in patients with st-segment elevation myocardial infarction and massive coronary thrombosis. Siberian Medical Journal (Tomsk). 2018;33(2):16–20. (In Russian).

2. Garganeva A.A., Borel K.N., Okrugin S.A., Kusheleva E.A. Predictors of the lethal outcome of acute myocardial infarction in young patients. Clinical medicine. 2017;95(8):713–718. (In Russian). DOI: 10.18821/0023-2149-2017-95-8-713-718

3. Ganiukov V.I., Shilov A.A., Bokhan N.S. et al. The Causes of Thrombosis in the Coronary Artery Stent. Int. J. Intervent. Cardioangiol. 2012;28:26–30.

4. Perek B., Liesiar M., Jemielу М. Spontaneus resolution of iatrogenic disstction of the left main coronarу arterу ext ending to the thoracic and abdominal aorta. Adv. Jnterv. Cardiol. 2013;9(2):194–197. DOI:10.5114/pwki.2013.3546

5. Joo S.J. Mechanisms of Platelet Activation and Integrin αIIβ3. Korean Circ. J. 2012;42(5):295–301. DOI: 10.4070/kcj.2012.42.5.295

6. Bedjaoui A., Allal K., Lounes M.S. et. al. Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention. Cardiovasc. J. Afr. 2019;30(1):45–51. DOI: 10.5830/CVJA-2018-063

7. Rgeeb A.N., Alsalkh H.A. et al. Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact. Med. Arch. 2020;74(4):265–269. DOI: 10.5455/medarh.2020.74.265-269

8. Fischer F., Buxy S., Kurz D.J. et. al. Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am. J. Cardiol. 2021;139: 15–21. DOI: 10.1016/j.amjcard.2020.09.054

9. Pevzner D.V., Staroverov I.I., Samko A.M. et. al. Glycoprotein IIbIIIa antagonist monafram in primary angioplasty of patients with acute coronary syndrome without ST segment elevation. Caridology. 2010;50(6):22–26. (In Russian).

10. Gerasimov A.M., Tereshchenko A.S., Merkulov E.V., Samko A.N. The phenomenon of non-restored coronary blood flow (no-reflow) in the practice of an endovascular surgeon. Bulletin of Radiology and Radiology. 2014;1:51–55. (In Russian).

11. Dannenberg L., Wolff G., Naguib D. et al. Safety and efficacy of Tirofiban in STEMI-patients. Int. J. Cardiol. 2019;274:35–39. DOI: 10.1016/j.ijcard.2018.09.052.